ALG3: A Protein Targeted for Drug Development and Biomarker Research

Target Name: ALG3

NCBI ID: G10195

ALG3

Other Name(s): D16Ertd36e | Alg3 alpha-1,3-mannosyl transferase | asparagine-linked glycosylation 3, alpha-1,3- mannosyltransferase homolog | dol-P-Man-dependent alpha(1-3)-mannosyltransferase | asparagine-linked glycosylation protein 3 homolog | CDGS6 | Carbohydrate deficient glycoprotein syndrome type IV | Man5GlcNAc2-PP-Dol mannosyltransferase | Asparagine-linked glycosylation 3 homolog (yeast, alpha-1,3-mannosyltransferase) | dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase | Not56-like protein | not | Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase | Not56 | asparagine-linked glycosylation 3 homolog (yeast, alpha-1,3-mannosyltransferase) | CDGS4 | Asparagine-linked glycosylation 3 homolog (S. cerevisiae, alpha-1,3-mannosyltransferase) | Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase | Asparagine-linked glycosylation protein 3 homolog | Dol-P-Man-dependent alpha(1-3)-mannosyltransferase | ALG3 alpha-1,3- mannosyltransferase | ALG3 variant 1 | CDG1D | asparagine-linked glycosylation 3 homolog (S. cerevisiae, alpha-1,3-mannosyltransferase) | carbohydrate deficient glycoprotein syndrome type IV | dolichyl-phosphate-mannose--glycolipid alpha-mannosyltransferase | NOT | ALG3 alpha-1,3- mannosyltransferase, transcript variant 1 | NOT56L | Dol-P-Man dependent alpha(1-3)-mannosyltransferase | ALG3_HUMAN | Dolichyl-phosphate-mannose--glycolipid alpha-mannosyltransferase | Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase (isoform a)

ALG3: A Protein Targeted for Drug Development and Biomarker Research

ALG3 (D16Ertd36e) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and is known for its role in the development and maintenance of tissues such as the liver, pancreas, and muscle.

Recent studies have identified ALG3 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for drug development, as it is able to interact with a wide range of small molecules and antibodies.

One of the key advantages of ALG3 as a drug target is its ability to be targeted with small molecules that are already available and have a low potential for toxicity. This has led to a surge in research on ALG3 and its potential therapeutic uses.

In addition to its potential as a drug target, ALG3 is also being investigated as a biomarker for a variety of diseases. Its expression has been shown to be elevated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it a promising biomarker for these conditions, and has led to further research into its potential uses as a diagnostic tool.

Overall, ALG3 is a protein that has the potential to be a valuable drug target and biomarker for a wide range of diseases. Its unique structure and function make it an attractive target for drug development, and its potential as a biomarker for a variety of conditions makes it an important area of research.

Protein Name: ALG3 Alpha-1,3- Mannosyltransferase

Functions: Adds the first Dol-P-Man derived mannose in an alpha-1,3 linkage to Man5GlcNAc2-PP-Dol

The "ALG3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALG3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets